BioNTech buys German site from Novartis: the advisor

BioNTech, has agreed to acquire the GMP certified manufacturing facility in Marburg, Germany of Novartis, a listed Switzerland-based company engaged in pharmaceutical company. The transaction will increase BioNTech’s Covid-19 vaccine production capacity by up to 750m doses per year, or over 60m doses per month, once fully operational. The transaction is expected to complete in the fourth quarter of 2020 and is subject to regulatory approval and customary closing conditions.

Freshfields Bruckhaus Deringer acted as legal advisor to Novartis.